Safety and Effectiveness Study of Tocilizumab in Patients With Severe COVID-19

Sponsor
Hospital Italiano de Buenos Aires
Study ID
NCT04924829
Status
Unknown

Conditions

  • Severe COVID 19 Pneumonia
  • Tocilizumab

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab — DRUG
    Tocilizumab received as a single intravenous infusion over the period of 60 minutes. Dose of 8 mg/kg, maximum dose of 800 mg.

Study Details

Retrospective observational cohort study to evaluate the safety and effectiveness of tocilizumab in the treatment of severe COVID-19 pneumonia

Key Dates

Start date
Jun 1, 2021
Status verified
Jun 2021
Primary completion
Jul 1, 2021
Completion
Aug 1, 2021

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Tocilizumab
    Group that received tocilizumab (8mg/kg, maximum dose 800 mg, only once) while being admitted with severe COVID-19 pneumonia.
  • Arm: Non-tocilizumab
    Group that did not receive tocilizumab but share the same indication according to the elegibility criteria for it as the tocilizumab group while admitted with severe COVID-19 pneumonia.

Primary Outcome Measure

28-day mortality [ Time Frame: 28 days from hospital admission ]

Central Contacts